Back

Clopidogrel versus aspirin for secondary prevention of coronary artery disease stratified by age: an individual patient data meta-analysis of 28,982 patients from 7 randomized trials

30 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Targeting platelets post-percutaneous coronary intervention Antiplatelet Drugs ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Daniele Giacoppo

AOU Policlinico - G. Rodolico San Marco, Catania (Italy)

6 More presentations in this session

Presentation thumbnail
Short-term DAPT followed by P2Y12 monotherapy versus standard-term DAPT after PCI for ACS: an updated systematic review and meta-analysis of randomised controlled trials
Associate Professor M. Monaghan (Enniskillen, GB)
Abstract Slides
Presentation thumbnail
Impact of age on comparative outcomes of abbreviated versus standard antiplatelet therapy in patients at high bleeding risk: a pre-specified analysis from the MASTER-DAPT trial
Doctor A. Landi (Lugano, CH)
Abstract Slides
Presentation thumbnail
Ticagrelor-based dual antiplatelet therapy versus aspirin monotherapy after CABG: a systematic review and meta-analysis of randomized controlled trials
Mr R. Goes (Asa Sul Brasilia, BR)
Abstract Slides
Presentation thumbnail
Differential prognostic value of platelet reactivity and CYP2C19 phenotype in high bleeding risk patients undergoing PCI: insights from the PTRG-DES Registry
Doctor J. Cha (Seoul, KR)
Abstract Slides
Presentation thumbnail
Potent P2Y12 inhibitor monotherapy without aspirin early after percutaneous coronary intervention: the NEO-MINDSET Platelet Function Substudy
Doctor P. Guimaraes (Sao Paulo, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Targeting platelets post-percutaneous coronary intervention

The Event

Event poster

ESC Congress 2026

30 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Aspirin versus clopidogrel beyond 1 month after acute coronary syndrome with high bleeding risk or ST-elevation myocardial infarction: pre-specified subanalyses of the STOPDAPT-3
1 September 2025
thumbnail
Congress Presentation
Statins for secondary prevention of coronary artery disease in patients aged 80 years or older: a nation-wide propensity score-based analysis
26 April 2024
thumbnail
Congress Presentation
Effectiveness and safety of apixaban vs warfarin among older venous thromboembolism patients: a subgroup analysis of age
27 August 2021
thumbnail
Congress Presentation
Meta-analysis assessing cardiovascular outcomes with febuxostat versus allopurinol for patients with gout
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources